AnatomyDiseasesChemicals and DrugsPsychiatry and PsychologyPhenomena and Processes
Blast CrisisLeukemia, Myelogenous, Chronic, BCR-ABL PositiveBenzamidesPiperazinesPyrimidinesLeukemia, MyeloidFusion Proteins, bcr-ablLeukemia, Myeloid, AcuteAcute DiseaseCrisis InterventionBlast InjuriesLeukemia, Myeloid, Accelerated PhasePhiladelphia ChromosomeChromosomes, Human, 21-22 and YGenes, ablLeukemia, Myeloid, Chronic-PhaseGranulocyte-Macrophage Progenitor CellsGene Expression Regulation, LeukemicLeukemia, LymphoidThyroid CrisisK562 CellsLeukemiaProto-Oncogene Proteins c-bcrAnemia, Refractory, with Excess of BlastsBone Marrow
AcuteDifferentiationMalignanciesCellsPediatric chronic myeloidImatinibPatientsPhiladelphiaDiagnosed with chronic myeloidProliferationNeoplasmsTreatment-Free RemissionMutationsPhaseAllogeneicPeripheral bloodTyrosine kinase inChronic myelogenous leukeMyeloproliferativeDiseaseBoneCancerHighly expressedClonalLymphaticPlateletDetectionNUP98Fusion gene
Acute16
  • The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). (mayo.edu)
  • However resistance to TKIs occurs in 10% of patients in chronic phase and 80% patients in the acute phase of blast crisis. (actrec.gov.in)
  • We aim to generate molecular profiles of CD34+ cells isolated from peripheral blood of TKI-sensitive and -resistant chronic myeloid leukemia patients in chronic as well as acute phase. (actrec.gov.in)
  • While chronic myeloid leukemia (CML) can be controlled with targeted therapies, this disease can be lethal if it advances or is diagnosed in an acute "blast" phase. (sciencedaily.com)
  • The findings also have implications for acute myeloid leukemia (AML) and other blood cancers. (sciencedaily.com)
  • Acute myeloid leukemia (AML) with t(9;22)(q34;q11), also known as AML with BCR-ABL1, is a rare, provisional entity in the WHO 2016 classification and is considered a high-risk disease according to the European LeukemiaNet 2017 risk stratification. (lu.se)
  • Those with chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, and those with CML whose tumors have a T315I mutation, were found to have improved efficacy when olverembatinib was given. (cancernetwork.com)
  • Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are myeloid blood cell malignancies that show great heterogeneity. (biomedcentral.com)
  • The mechanism of upregulation becomes relevant when one considers that c-Kit is usually highly expressed on the surface of acute myeloid leukemia (AML) cells [23 24 Unfortunately this study did not conduct any experiments to assess the downstream consequences of induction in LAMA-84 cells. (bioinf.org)
  • Aim: We examined the association between diabetes and survival in patients with acute and chronic myeloid leukemia and the association of leukemia with glycemic control. (sciencegate.app)
  • The progression of low-risk del(5q) myelodysplastic syndrome to acute myeloid leukemia is increased when associated with mutations of TP53, or with additional chromosomal abnormalities. (biomedcentral.com)
  • FOXP1 was also found activated in other patients with myelodysplasia and acute myeloid leukemia, showing that it is an important, recurrent event. (biomedcentral.com)
  • Finally, our results may suggest a possible broader role of FOXP1 in the pathogenesis and progression of myelodysplasia and acute myeloid leukemia. (biomedcentral.com)
  • These malignancies are further characterized by the maturity and differentiation of the individual cell types and are divided into acute leukemias such as acute myeloid leukemia and acute lymphoblastic leukemia and chronic leukemias such as chronic myeloid leukemia and chronic lymphocytic leukemia. (medscape.com)
  • Blastic crisis is essentially like acute leukemia and is chemo refractory with a median survival of 3 to 6 months [7]. (waocp.com)
  • The blast phase appears and behaves like the acute form of myeloid leukemia. (schoolandyouth.org)
Differentiation7
  • When overexpressed by transfection, NME3 suppressed granulocyte differentiation and induced apoptosis of myeloid precursor cells. (wikipedia.org)
  • Chronic myeloid leukemia (CML) results from BCR-ABL oncogene, which blocks CML cells differentiation and protects these cells from apoptosis. (jcancer.org)
  • The expression of RUNX1 mutant in ASXL1 -mutated myeloid cells augmented proliferation, blocked differentiation, and increased self-renewal activity. (biomedcentral.com)
  • The natural history of CML has a triphasic clinical course comprising of an initial chronic phase (CP), which is characterized by expansion of functionally normal myeloid cells, followed by an accelerated phase (AP) and finally a more aggressive blast phase (BP), with loss of terminal differentiation capacity. (genome.jp)
  • Leukocyte differentiation antigens often represent important markers for the diagnosis, classification, prognosis, and therapeutic targeting of myeloid leukemia. (biomedcentral.com)
  • Therefore, VSTM1-v1 might represent an important myeloid leukocyte differentiation antigen and provide a potential target for the diagnosis and treatment of leukemia. (biomedcentral.com)
  • VSTM1 ( V-set and transmembrane domain-containing 1 ) encodes a potential leukocyte differentiation antigen that is highly expressed in myeloid cells, but silenced in multiple leukemia cell lines [ 1 ]. (biomedcentral.com)
Malignancies2
  • The present study demonstrated the biological and functional evidence for the critical role of RUNX1 -MT in ASXL1 -mutated leukemia in the pathogenesis of myeloid malignancies. (biomedcentral.com)
  • Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies. (cdc.gov)
Cells23
  • p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells. (southernbiotech.com)
  • Chronic myeloid leukemia (CML) is a clonal expansion of the progenitor hematopoietic stem cells arising from the existence of the fusion BCR-ABL oncogene, that represents 15%-20% of the newly diagnosed cases of leukemia patients [ 1 - 2 ]. (jcancer.org)
  • Co-expression of two mutant genes increased myeloid stem cells in animal model, suggesting that cooperation of RUNX1 and ASXL1 mutations played a critical role in leukemia transformation. (biomedcentral.com)
  • We have shown here that IM induces autophagy in CML blast crisis cell lines, CML primary cells, and p210BCR/ABL-expressing myeloid precursor cells. (lu.se)
  • BCR-ABL-transformed GMP as myeloid leukemic stem cells. (ca.gov)
  • During blast crisis of chronic myelogenous leukemia (CML), abnormal granulocyte macrophage progenitors (GMP) with nuclear beta-catenin acquire self-renewal potential and may function as leukemic stem cells (Jamieson et al. (ca.gov)
  • Expression of BCR-ABL in these cells reproducibly stimulated myeloid expansion in culture and generated leukemia-initiating cells specifically in the GMP compartment. (ca.gov)
  • In chronic myeloid leukemia, the bone marrow produces too many white blood cells. (medlineplus.gov)
  • However, as the condition progresses, immature white blood cells called myeloblasts (or blasts) accumulate in the blood and bone marrow. (medlineplus.gov)
  • In blast crisis, 30 percent or more of blood or bone marrow cells are myeloblasts. (medlineplus.gov)
  • Restoration of VSTM1-v1 expression inhibited myeloid leukemia cells' growth. (biomedcentral.com)
  • To determine whether it plays a role in leukemogenesis, we characterized its expression pattern and function in bone marrow cells from AML/CML patients and myeloid leukemia cell lines. (biomedcentral.com)
  • Therefore, we speculated that VSTM1-v1 expression might be associated with the maturity of myeloid cells. (biomedcentral.com)
  • A combination of CD34/CD117/CD13/CD16 staining showed that VSTM1-v1 expression in myeloid cells was positively correlated with cell maturation state. (biomedcentral.com)
  • Of note LAMA-84 cells were originally derived from a chronic myeloid leukemia (CML) patient undergoing blast crisis [22]. (bioinf.org)
  • Histological sections indicated that the BM was cellular at 80%, including numerous dystrophic megakaryocytes, reduction of normoblastic erythroid elements, and increase of myeloid immature cells with dysplastic morphology. (biomedcentral.com)
  • These are the malignant proliferations of abnormal clones of white blood cells within the bone marrow that are broadly categorized into lymphoid and myeloid neoplasms depending on the type of white cell proliferation. (medscape.com)
  • The white blood cells (leukocytes) are further divided into phagocytes or myeloid (neutrophils, eosinophils, basophils, monocytes) and immunocytes or lymphoid (lymphocytes). (medscape.com)
  • CML causes the rapid proliferation and growth of mostly myeloid cells within the bone marrow. (healthandconditions.com)
  • This test reveals all types of granulocytes, normally including myeloid cells that are mature. (healthandconditions.com)
  • Determining the CML phase is based primarily on the number of immature white blood cells (blasts) in the patient's blood and bone marrow. (schoolandyouth.org)
  • In the accelerated phase, the number of immature blast cells has risen, and sometimes new chromosomal changes, in addition to the Ph chromosome, will occur. (schoolandyouth.org)
  • It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. (bvsalud.org)
Pediatric chronic myeloid5
  • Priapism at diagnosis of pediatric chronic myeloid leukemia: Data derived from a large cohort of children and teenagers and a narrative review on priapism management (Suttorp M et al. (cml-foundation.org)
  • Patient-reported long-term outcome following allogeneic hematopoietic stem cell transplantation in pediatric chronic myeloid leukemia (Schleicher O et al. (cml-foundation.org)
  • Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course (Delehaye F et al. (cml-foundation.org)
  • Outcome of pediatric chronic myeloid leukemia with management focusing on gene transcript levels (Al-Ghamblas I et al. (cml-foundation.org)
  • Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia (Kim Y et al. (cml-foundation.org)
Imatinib6
  • Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia (CML), but the frequency of resistance increases in advancing stages of disease. (lu.se)
  • Children with chronic myeloid leukemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicentre experience in Taiwan (Liu HC et al. (cml-foundation.org)
  • International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. (aboutscience.eu)
  • Radich J. Stem cell transplant for chronic myeloid leukemia in the imatinib era. (aboutscience.eu)
  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. (aboutscience.eu)
  • BACKGROUND: Point mutations of the BCR-ABL tyrosine kinase domain are considered the predominant cause of imatinib resistance in chronic myeloid leukemia. (bvsalud.org)
Patients21
  • Methods: We evaluated the IRF4 expression kinetics during tyrosine kinase inhibitor (TKI) treatment in a cohort of 116 chronic myeloid leukemia (CML) patients to elucidate its role in the disease course. (karger.com)
  • Pia Raanani Introduction: Data regarding the prevalence of paraproteinemia in patients with chronic myeloid leukemia (CML) are lacking. (karger.com)
  • Alexander Kiani Introduction: Treatment-free remission (TFR) is increasingly considered as treatment goal for patients with chronic myeloid leukemia (CML), but information. (karger.com)
  • The mutational landscape exhibited a similar pattern as recently described in patients with chronic myeloid leukemia (CML) in myeloid blast crisis (BC). (lu.se)
  • Last May, Gleevec received FDA approval for the treatment of patients with chronic myeloid leukemia in the blast crisis, accelerated phase, or in chronic phase after failure of interferon-alfa. (cancernetwork.com)
  • Ahead of the 2017 ASCO Annual Meeting, we discuss the discontinuation of TKIs in some chronic myeloid leukemia patients. (cancernetwork.com)
  • A major molecular response at 3 months appears to increase the probability of overall survival in patients treated with ponatinib for chronic-phase chronic myeloid leukemia in the phase 2 PACE trial. (cancernetwork.com)
  • The drug is indicated in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase, blast crisis, accelerated phase, or in chronic phase after the failure of interferon-alpha treatment. (pharmacytimes.com)
  • In addition, patients receiving nilotinib demonstrated a lower rate of progression to the accelerated or blast stage of CML. (medscape.com)
  • EAST HANOVER, N.J., Feb. 19 -- (Healthcare Sales & Marketing Network) -- Novartis announced today that Tasigna (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (salesandmarketingnetwork.com)
  • The current clinical practice for patients affected by chronic myeloid leukemia (CML) is based on the evaluation of second generation alternatives following therapeutic failure that leads to a lengthening of patients' management times and a consequent negative impact in terms of quality of life. (aboutscience.eu)
  • Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. (aboutscience.eu)
  • DESIGN AND METHODS: The changes of expression of mutant BCR-ABL-positive alleles after cessation of tyrosine kinase inhibitor treatment were examined in 19 patients with chronic myeloid leukemia harboring different mutations in a longitudinal follow-up. (bvsalud.org)
  • Most of the patients in blastic phase have a myeloid phenotype while 25% show a pre B lymphoblastic phenotype [1]. (waocp.com)
  • Newly diagnosed adult and pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (hikma.com)
  • Differences in Variants in the Structural Domain of BCR-ABL1 Kinase between Chinese Han and Minority Patients with Chronic Myeloid Leukemia by Sanger Sequencing and Next-Generation Sequencing. (cdc.gov)
  • Clinical characteristics, disease evolution and survival in patients with chronic myeloid leukemia, BCR-ABL1 (+) and T315I mutation. (cdc.gov)
  • The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation. (cdc.gov)
  • Phase of CML-Patients who have either accelerated or blast phase CML have a less favorable prognosis than those who have chronic phase CML. (schoolandyouth.org)
  • Blasts in the blood-Patients who have a high number of blasts in the blood have a less favorable prognosis. (schoolandyouth.org)
  • What Do We Need To Know About Pregnancy, and Family Planning for Patients Diagnosed With Chronic Myeloid Leukemia? (medscape.com)
Philadelphia2
Diagnosed with chronic myeloid1
  • This study focuses on children, adolescents and young adults who have been diagnosed with chronic myeloid leukemia (CML) and whose level of disease is very low (molecular remission). (cedars-sinai.edu)
Proliferation1
  • BCR-ABL fusion gene leads to proliferation of myeloid elements by encoding a protein with tyrosine kinase activity [5]. (waocp.com)
Neoplasms1
  • Additional sex combs-like 1 ( ASXL1 ) mutations have been described in all forms of myeloid neoplasms including chronic myelomonocytic leukemia (CMML) and associated with inferior outcomes, yet the molecular pathogenesis of ASXL1 mutations ( ASXL1 -MT) remains poorly understood. (biomedcentral.com)
Treatment-Free Remission1
  • Correction: HLA Polymorphisms Are Associated With Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. (cdc.gov)
Mutations4
  • Previously, we observed that transcription factor RUNX1 mutations ( RUNX1 -MT) coexisted with ASXL1 -MT in CMML and at myeloid blast phase of chronic myeloid leukemia. (biomedcentral.com)
  • The contribution of RUNX1 mutations in the pathogenesis of myeloid transformation in ASXL1 -mutated leukemia, however, remains unclear. (biomedcentral.com)
  • Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. (aboutscience.eu)
  • ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. (cdc.gov)
Phase17
  • Musashi2(Msi2)-Numb pathway de-regulation is a molecular mechanism underlying the transition of chronic phase Ph + CML to deadly blast crisis, particularly in cases with a NUP98/HOXA9 fusion from a t(7;11)(p15;p15). (biomedcentral.com)
  • While fusion of c-ABL and BCR is believed to be the primary cause of the chronic phase of CML, progression to blast crisis requires other molecular changes. (genome.jp)
  • The condition consists of three phases: the chronic phase, the accelerated phase, and the blast phase (or blast crisis). (medlineplus.gov)
  • Researchers believe that additional genetic changes play a role in the progression of the chronic phase of chronic myeloid leukemia to the accelerated phase and blast crisis. (medlineplus.gov)
  • Additionally, in CML-AP/BC (accelerated phase/blast crisis), which clinically behaves like AML, VSTM1 expression levels were much lower than those in CML-CP (chronic phase, P = 0.003, Table 1 ). (biomedcentral.com)
  • Treatment protocols for chronic myelogenous leukemia (CML) are provided below for chronic phase, accelerated phase, and blast phase. (medscape.com)
  • [ 6 ] Additionally, a follow-up study showed significant improvement in 8-year event survival, freedom from progression to accelerated phase or blast phase, and overall survival. (medscape.com)
  • 1% at 12 months had inferior EFS and higher rate of progression to accelerated- or blast-phase CML, while those with an MMR ( BCR-ABL1 ≤ 0.1%) by 18 months had no progression to advanced disease and 95% EFS at 7 years. (medscape.com)
  • Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations - Review (Sembill S et al. (cml-foundation.org)
  • Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors (Nishiyam-Fujita Y et al. (cml-foundation.org)
  • Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. (aboutscience.eu)
  • Chronic phase (CP), accelerated phase (AP) and blast crisis (BP). (waocp.com)
  • The third phase that CML causes is known as blast crisis. (healthandconditions.com)
  • The phase of your chronic myeloid leukemia (CML) plays a large part in determining the type of treatment you'll receive. (schoolandyouth.org)
  • If untreated, chronic phase CML will eventually progress to accelerated phase CML and/or blast phase CML. (schoolandyouth.org)
  • If untreated, accelerated phase CML will eventually transform to blast phase CML. (schoolandyouth.org)
  • The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. (bvsalud.org)
Allogeneic1
  • Successful eradication of chronic myeloid leukemia in a child despite allogeneic graft rejection (Vuorenoja S et al. (cml-foundation.org)
Peripheral blood2
Tyrosine kinase in1
  • Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment (Karadas N et al. (cml-foundation.org)
Chronic myelogenous leuke1
Myeloproliferative2
  • Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of a pluripotent stem cell. (genome.jp)
  • found to have myeloproliferative dis- ic myeloid leukaemia (CML). (who.int)
Disease2
  • Our results suggest that the molecular characteristics of AML with t(9;22)/BCR-ABL1 and CML in myeloid BC are similar and do not support a distinction of the two disease entities based on their underlying molecular alterations. (lu.se)
  • Chronic Myeloid Leukemia is a stem cell clonal disease with an annual incidence of 1-1.5 per 100,000 persons. (waocp.com)
Bone3
Cancer2
  • A team of researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia, a type of cancer that remains difficult to treat and is marked by frequent relapse. (sciencedaily.com)
  • The cancer is classified into three phases: chronic, accelerated, and blast crisis. (healthandconditions.com)
Highly expressed1
Clonal1
  • Trastorno hematopoyético clonal causado por un defecto genético en las CÉLULAS MADRE PURIPOTENTES. (bvsalud.org)
Lymphatic1
  • Myeloid leukaemias are no longer dence of lymphatic cancers. (who.int)
Platelet1
  • Impact of tyrosine kinase inhibitors applied for first-line chronic myeloid leukemia treatment on platelet function in whole blood of healthy volunteers in vitro (Eckart F et al. (cml-foundation.org)
Detection1
  • RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia. (cdc.gov)
NUP983
  • Herein we describe a t(7;11)(p15;p15) originating a NUP98 fusion with HOXA13, at 7p15, in a 39 year-old man in blast crisis of Ph-positive CML. (biomedcentral.com)
  • To the best of our knowledge, this is the first molecular characterization of NUP98/HOXA13 fusion in blast crisis of Ph + CML. (biomedcentral.com)
  • We investigated MSI2 regulation in the first case of Ph-positive CML in blast crisis with t(7;11) and NUP98/HOXA13 fusion gene. (biomedcentral.com)
Fusion gene1
  • In 5 to 10 percent of cases of chronic myeloid leukemia, the BCR-ABL1 fusion gene is created by complex rearrangements that involve other chromosomes in addition to chromosomes 9 and 22. (medlineplus.gov)